Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.35 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037526 | 0.82 | PI4KB (0.33) | KDM4EHSD17B10NOS3NOS2PI4KB | |
| SCHEMBL6466538 | 0.82 | PI4KB (0.33) | KDM4EHSD17B10NOS3NOS2PI4KB | |
| SCHEMBL6469091 | 0.82 | PI4KB (0.33) | KDM4EHSD17B10NOS3NOS2PI4KB | |
| SCHEMBL6469032 | 0.82 | PI4KB (0.33) | KDM4EHSD17B10NOS3NOS2PI4KB | |
| SCHEMBL5133501 | 0.79 | KMT2A (0.47) | ANO1CNR1CACNA1GCACNA1HCNR2 | |
| SCHEMBL5131540 | 0.77 | KDM4E (0.38) | KDM4EHSD17B10NOS3NOS2PI4KB | |
| SCHEMBL5043113 | 0.76 | HTR1A (0.41) | KDM4EHSD17B10NOS3NOS2KCNH2 | |
| SCHEMBL6470690 | 0.76 | NOS3 (0.36) | KDM4EHSD17B10NOS3NOS2KCNH2 | |
| SCHEMBL5130593 | 0.75 | CA2 (0.42) | KDM4EHSD17B10NOS3NOS2KCNH2 | |
| SCHEMBL5133792 | 0.74 | SMN1; SMN2 (0.49) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | KDM4E 3151/4885HSD17B10 1618/4885NOS3 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.